GeneDx Q3 Revenue Up 5% but Adjusted Profit Halves; Guidance Trimmed
WGS has more than doubled off its 52-week low of $32.21 on elevated volume (2.1× avg).
Summary
Revenue rose 5% to $123.1M, but adjusted net income fell to $8.6M from $16.1M a year ago and GAAP net loss widened to $12.3M from $7.6M. Exome and genome volume grew 25% to 32,134 tests, yet adjusted gross margin slipped to 72% from 74%, so the volume growth is not converting into profit at last year's rate. Management trimmed full-year exome and genome revenue growth guidance to at least 17% from at least 20% and now expects roughly $12M of adjusted net income for the year, with Q4 revenue guided to $135M. The balance sheet shows $171.1M of cash and marketable securities against $146.2M of long-term debt, and the nine-month cash flow statement shows $72.0M used in operations. This is the first hard look at the post-Fabric Genomics cost structure after the $31.3M impairment and debt refinancing earlier this year.
At the time of this announcement, WGS was trading at $65.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $32.21 to $170.87. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.